Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2015 (2015), Article ID 412903, 8 pages
http://dx.doi.org/10.1155/2015/412903
Review Article

Individualized Therapy with Ranibizumab in Wet Age-Related Macular Degeneration

1Clínica Universidad de Navarra, Avenida de Pío XII 36, 31008 Pamplona, Spain
2Sociedad Española de Retina y Vítreo (SERV), C/ Xosé Chao Rego 8, 15705 Santiago de Compostela, Spain
3RETICS OFTARED (RD12/0034) “Prevention Early Detection and Treatment of the Prevalent Degenerative and Chronic Ocular Pathology”, Institute of Health Carlos III, C/ Sinesio Delgado 4, 28029 Madrid, Spain
4Hospital Universitario Ramon y Cajal, Carretera de Colmenar, km 9, 28034 Madrid, Spain
5Vissum Madrid, Santa Hortensia 58, 28002 Madrid, Spain
6Hospital de Bellvitge, C/ Feixa Llarga s/n, L’Hospitalet de Llobregat, 08907 Barcelona, Spain
7Hospital de San Eloy, Avenida Antonio Miranda 5, 48902 Baracaldo, Spain
8Hospital Universitario de Albacete, Avenida de Almansa s/n, 02006 Albacete, Spain
9Hospital Vall D’Hebron, Passeig de la Vall d’Hebron 119–129, 08035 Barcelona, Spain
10Instituto Oftalmológico Gómez-Ulla, Calle Maruja Mallo 3, 15706 Santiago de Compostela, Spain
11IOBA, Hospital Clínico Universitario de Valladolid, Paseo de Belén 17, 47011 Valladolid, Spain
12Complejo Hospitalario Universitario Insular Materno Infantil de Gran Canaria, Avenida Marítima del Sur s/n, 35016 Las Palmas de Gran Canaria, Spain
13Hospital Universitario Virgen de la Victoria, Campus de Teatinos s/n, 29010 Málaga, Spain
14Institut de la Macula i de la Retina, Carrer de Vilana 12, 08022 Barcelona, Spain
15Hospital General de Valencia, Avenida Tres Cruces 2, 46014 Valencia, Spain
16Hospital la Paz, Paseo de la Castellana 261, 28046 Madrid, Spain
17Hospital la Fe, Avenida de Fernando Abril Martorell 106, 46026 Valencia, Spain

Received 13 October 2014; Accepted 10 March 2015

Academic Editor: Juliana L. Dreyfuss

Copyright © 2015 Alfredo García-Layana et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Klein, B. E. K. Klein, S. C. Tomany, and S. E. Moss, “Ten-year incidence of age-related maculopathy and smoking and drinking: the Beaver Dam Eye study,” The American Journal of Epidemiology, vol. 156, no. 7, pp. 589–598, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. C. Sainz-Gómez, P. Fernández-Robredo, Á. Salinas-Alamán et al., “Prevalence and causes of bilateral blindness and visual impairment among institutionalized elderly people in Pamplona, Spain,” European Journal of Ophthalmology, vol. 20, no. 2, pp. 442–450, 2010. View at Google Scholar · View at Scopus
  3. J. Ambati, B. K. Ambati, S. H. Yoo, S. Ianchulev, and A. P. Adamis, “Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies,” Survey of Ophthalmology, vol. 48, no. 3, pp. 257–293, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. D. M. Brown, P. K. Kaiser, M. Michels et al., “Ranibizumab versus verteporfin for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1432–1444, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. D. F. Martin, M. G. Maguire, G.-S. Ying, J. E. Grunwald, S. L. Fine, and G. J. Jaffe, “Ranibizumab and bevacizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 364, no. 20, pp. 1897–1908, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Trichonas and P. K. Kaiser, “Aflibercept for the treatment of age-related macular degeneration,” Ophthalmology and Therapy, vol. 2, no. 2, pp. 89–98, 2013. View at Publisher · View at Google Scholar
  8. J. M. Ruiz-Moreno, L. Arias-Barquet, F. Armadá-Maresca et al., “Guidelines of clinical practice of the SERV: treatment of exudative age-related macular degeneration (AMD),” Archivos de la Sociedad Espanola de Oftalmologia, vol. 84, no. 7, pp. 333–344, 2009. View at Google Scholar · View at Scopus
  9. N. M. Bressler, “Early detection and treatment of neovascular age-related macular degeneration,” The Journal of the American Board of Family Practice, vol. 15, no. 2, pp. 142–152, 2002. View at Google Scholar · View at Scopus
  10. A. F. Cruess, A. Berger, K. Colleaux et al., “Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration,” Canadian Journal of Ophthalmology, vol. 47, no. 3, pp. 227–235, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. W. Amoaku, “Ranibizumab: the clinician's guide to commencing, continuing, and discontinuing treatment,” Eye, vol. 23, no. 11, pp. 2140–2142, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. G. A. Lalwani, P. J. Rosenfeld, A. E. Fung et al., “A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study,” The American Journal of Ophthalmology, vol. 148, no. 1, pp. 43.e1–58.e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. F. G. Holz, W. Amoaku, J. Donate et al., “Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study,” Ophthalmology, vol. 118, no. 4, pp. 663–671, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. U. Chakravarthy, S. P. Harding, C. A. Rogers et al., “Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial,” The Lancet, vol. 382, no. 9900, pp. 1258–1267, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Menghini, M. M. Kurz-Levin, C. Amstutz et al., “Response to ranibizumab therapy in neovascular AMD. An evaluation of good and bad responders,” Klinische Monatsblätter für Augenheilkunde, vol. 227, no. 4, pp. 227–248, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. H. J. Shin, H. Chung, and H. C. Kim, “Correlation of foveal microstructural changes with vision after anti-vascular endothelial growth factor therapy in age-related macular degeneration,” Retina, vol. 33, no. 5, pp. 964–970, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. M. L. Bidot, L. Malvitte, S. Bidot, A. Bron, and C. Creuzot-Garcher, “Etude preliminaire sur l'efficacité de trois injec-tions intravitreennes de bevacizumab dans le traitement de la degenrescence maculaire lieé à l'agê exsudative,” Journal Français d'Ophtalmologie, vol. 34, no. 6, pp. 376–381, 2011. View at Publisher · View at Google Scholar
  18. P. J. Mekjavic, A. Kraut, M. Urbancic, E. Lenassi, and M. Hawlina, “Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections,” Acta Ophthalmologica, vol. 89, no. 7, pp. 647–653, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Berg, T. R. Pedersen, L. Sandvik, and R. Bragadóttir, “Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol,” Ophthalmology, vol. 122, no. 1, pp. 146–152, 2015. View at Publisher · View at Google Scholar
  20. H. Oubraham, S. Y. Cohen, S. Samimi et al., “Inject and extend dosing versus dosing as needed: a comparative retrospective study of ranibizumab in exudative age-related macular degeneration,” Retina, vol. 31, no. 1, pp. 26–30, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Monés, “A review of ranibizumab clinical trial data in exudative age-related macular degeneration and how to translate it into daily practice,” Ophthalmologica, vol. 225, no. 2, pp. 112–119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Monés, M. Biarnés, F. Trindade, and R. Casaroli-Marano, “FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 250, no. 12, pp. 1737–1744, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Seidel, C. Werner, M. Weger, I. Steinbrugger, and A. Haas, “Combination treatment of photodynamic therapy with verteporfin and intravitreal ranibizumab in patients with retinal angiomatous proliferation,” Acta Ophthalmologica, vol. 91, no. 6, pp. 482–485, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Calvo, A. Ferreras, F. Al Adel, Y. Wang, and M. H. Brent, “Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab,” British Journal of Ophthalmology, 2014. View at Publisher · View at Google Scholar
  25. P. Mitchell, J.-F. Korobelnik, P. Lanzetta et al., “Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials,” British Journal of Ophthalmology, vol. 94, no. 1, pp. 2–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. W. M. K. Amoaku, “The Royal College of Ophthalmologists interim recommendations for the management of patients with age-related macular degeneration,” Eye, vol. 22, no. 6, pp. 864–868, 2008. View at Publisher · View at Google Scholar
  27. S. A. Zweifel, M. Engelbert, K. Laud, R. Margolis, R. F. Spaide, and K. B. Freund, “Outer retinal tubulation a novel optical coherence tomography finding,” Archives of Ophthalmology, vol. 127, no. 12, pp. 1596–1602, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. P. J. Rosenfeld, H. Shapiro, L. Tuomi, M. Webster, J. Elledge, and B. Blodi, “Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials,” Ophthalmology, vol. 118, no. 3, pp. 523–530, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. A. H. C. Koh, L.-J. Chen, S.-J. Chen et al., “Polypoidal choroidal vasculopathy: evidence-based guidelines for clinical diagnosis and treatment,” Retina, vol. 33, no. 4, pp. 686–716, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. A. N. Stangos, J. S. Gandhi, J. Nair-Sahni, H. Heimann, C. J. Pournaras, and S. P. Harding, “Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab,” The American Journal of Ophthalmology, vol. 150, no. 5, pp. 666–673, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Schaal, H. J. Kaplan, and T. H. Tezel, “Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?” Ophthalmology, vol. 115, no. 12, pp. 2199–2205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. J. R. De Geus, M. J. Jager, G. P. M. Luyten, and G. Dijkman, “Shifting exudative age-related macular degeneration patients to ranibizumab after insufficient response to bevacizumab,” Acta Ophthalmologica, vol. 91, no. 5, pp. e411–e413, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Y. Ho, S. Yeh, T. W. Olsen et al., “Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors,” American Journal of Ophthalmology, vol. 156, no. 1, pp. 23–e2, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. M. W. Stewart, P. J. Rosenfeld, F. M. Penha et al., “Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye),” Retina, vol. 32, no. 3, pp. 434–457, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. T. M. Ranchod, S. K. Ray, S. A. Daniels, C. J. Leong, T. D. Ting, and A. Z. Verne, “LUCEDEX: a prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration,” Retina, vol. 33, no. 8, pp. 1600–1604, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Gaudric and S. Y. Cohen, “When should anti-vascular endothelial growth factor treatment be stopped in age-related macular degeneration?” The American Journal of Ophthalmology, vol. 149, no. 1, pp. 4.e2–6.e2, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Rofagha, R. B. Bhisitkul, D. S. Boyer, S. R. Sadda, and K. Zhang, “Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP),” Ophthalmology, vol. 120, no. 11, pp. 2292–2299, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Monés and F. Gómez-Ulla, Degeneración Macular Asociada a la Edad, Prous Science, Barcelona, Spain, 2005.
  39. L. Arias, Actualización de Terapia Anti-VEGF en las Enfermedades de la Retina y Coroides, Elsevier España, 2010.
  40. L. Arias, I. Roman, C. Masuet-Aumatell et al., “One-year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections,” Retina, vol. 31, no. 7, pp. 1261–1267, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. M. A. Singer, C. C. Awh, S. Sadda et al., “HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration,” Ophthalmology, vol. 119, no. 6, pp. 1175–1183, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Y. Cohen, G. Mimoun, H. Oubraham et al., “Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the lumiere study,” Retina, vol. 33, no. 3, pp. 474–481, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. P. Mitchel, “Ranibizumab in age-related macular degeneration: a pooled analysis of European registries included in the LUMINOUS program,” in Proceedings of the WOC Meeting, 2012.
  44. C. B. Hoyng and AURA Steering Committee, “Retrospective analysis of the real world utilization of ranibizumab in AMD,” in Proceedings of the World Congress on Controversies in Ophthalmology (COPHy '13), Budapest, Hungary, April 2013.
  45. J. D. López, “Adherencia a las recomendaciones de la SERV para el manejo de pacientes con DMAE exudativa por parte de los especialistas retinologos,” in Actas del 17th Congreso de la Sociedad Española de Retina y Vitreo, Madrid, Spain, 2013.
  46. R. Casaroli-Marano, R. Gallego-Pinazo, C. T. Fernández-Blanco et al., “Age-related macular degeneration: clinical findings following treatment with antiangiogenic drugs,” Journal of Ophthalmology, vol. 2014, Article ID 346360, 6 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. A. García-Layana, L. Arias, M. S. Figueroa et al., “A Delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration,” Journal of Ophthalmology, vol. 2014, Article ID 595132, 10 pages, 2014. View at Publisher · View at Google Scholar